Skip to main content

Table 4 Comparison of adjusted demographic and baseline clinical characteristics of patients from the international observational studies (RIVER and XANTUS), studies from Japan (EXPAND and XAPASS)

From: International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

  RIVER XANTUS EXPAND XAPASS
Patients, n 5072 6784 7141 11,308
Patient characteristics
 Sex, male (%) 55.7 59.2 67.7 61.9
 Age, mean (SD) 69.5 (11.0) 71.5 (10.0) 71.6 (9.4) 73.1 (9.9)
 BMI (Kg/m2), mean (SD) 29.2 (5.7) 28.3 (5.0) NA 23.7 (3.8)
 Creatinine clearance (mL/min), mean (SD) 83.7 (35.6) NA 69.7 (26.2) 67.7 (28.9)
 < 15 mL/min (%) 0.02 0.3 NA 0.03
 ≥ 15 to < 30 mL/min (%) 0.7 1.1 1.9 2.8
 ≥ 30 to < 50 mL/min (%) 7.9 8.0 18.9 21.1
 ≥ 50 mL/min (%) 53.4 56.2 74.6 68.0
 Missing (%) 38.0 34.4 4.7 8.2
Rivaroxaban dose/dosing frequency
 10 mg once daily 105 (2.1) NA NA NA
 15 mg once daily 1008 (20.0) 1410 (20.8) NA NA
 20 mg once daily 3867 (76.5) 5336 (78.7) NA NA
 10 mg twice daily 10 (0.2) NA NA NA
 15 mg twice daily 29 (0.6) NA NA NA
 20 mg twice daily 22 (0.4) NA NA NA
 10/15/20 mg other dosing Regimen 12 (0.2) 35 (0.5) NA NA
 CHADS2 score, mean (SD) 1.9 (1.2) 2.0 (1.3) 2.1 (1.3) 2.2 (1.3)
 CHA2DS2-VASc score, mean (SD) 3.2 (1.6) 3.4 (1.7) 3.4 (1.7) NA
Comorbidity/medical history
 Congestive heart failure (%) 21.5 18.6 26.1 25.0
 Hypertension (%) 77.0 74.7 70.9 74.3
 Diabetes mellitus (%) 24.3 19.6 24.3 22.3
 History of stroke/systemic embolism/TIA (%) 13.4 19.0 24.1 23.7
Type of AF
 Paroxysmal (%) 34.2 40.7 44.8 NA
 Non-paroxysmal (persistent/permanent) (%) 31.6 40.8 55.2 NA
 First diagnosed (%) 34.2 18.5 NA NA